CUREVAC N.V. O.N.
Commented by Armin Schulz on September 27th, 2021 | 13:24 CEST
Valneva, Defence Therapeutics, CureVac - Second-tier vaccine makers offer high potential
The battle against the Coronavirus is still ongoing, although more and more people have been vaccinated with vector or mRNA vaccines. In Europe, an average of 60% of all people have received the vaccination. Herd immunity has not yet been achieved, in part because of vaccine skeptics who do not yet trust novel vaccines. New vaccines based on dead viruses promise to remedy the situation. This method has already been tried and tested in influenza vaccinations, for example. According to a study in Switzerland, about 70% of the unvaccinated would still be vaccinated if the method had already been tested. Herd immunity could thus be achieved, and everyday life could return to normal. So, which vaccine manufacturer that does not currently have an approved product could shake up the market?
Read
Commented by Nico Popp on September 9th, 2021 | 12:08 CEST
SMA Solar, Memiontec, CureVac: Doing good and earning money
When young founders develop business models, it is often a question of "purpose," i.e. the best possible (good) purpose of a company. For the new generation, money is no longer the only thing that counts. Instead, earning money and doing good are the watchwords. On the stock market, too, some companies make the world a little better. We look at three stocks and find out whether there is money to be made in them.
Read
Commented by Stefan Feulner on September 3rd, 2021 | 13:27 CEST
MorphoSys, Defence Therapeutics, CureVac, BioNTech - Dramatic need
While in Germany, 50.4 million citizens, or 60.7% of the population, are already fully vaccinated, and there is already discussion about booster vaccinations, the global average is just one in four. Thus, there is still an enormous demand for vaccines from various manufacturers. In addition to the French pharmaceutical Company Sanofi, a German vaccine producer could also celebrate a stock market comeback due to its second-generation vaccine.
Read
Commented by André Will-Laudien on September 1st, 2021 | 12:56 CEST
First Majestic Silver, Aztec Minerals, CureVac, Valneva - Opportunities upon opportunities!
So much for the summer lull! There is much more going on in the stock market than many thought. Gold and silver are making real leaps and bounds, as are the associated stocks. With the vaccination values, the chaff separated clearly from the wheat. Those that cannot currently deliver remain depressed in price. Nevertheless, the valuations of the remaining stocks are not low either. There is still hope for one or the other product's success. We take a closer look at a few stocks.
Read
Commented by André Will-Laudien on August 18th, 2021 | 10:43 CEST
Bayer, Cardiol Therapeutics, CureVac: The Champions League of Bio-Pharma!
Biopharmaceutics is the first port of call in the fight against a wide range of diseases. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. Biological effectiveness results from the entry of the drug into the diseased organism, its distribution in tissues, and the chemical reaction called metabolism. When dealing with recent pandemics, good advice is expensive, and research into pharmaceuticals costs billions. When an active ingredient is found and registered, the patent clock starts ticking for the inventor. As a result, the hope of the biopharmaceutical company is to remain the sole provider in their healing segment for as long as possible.
Read
Commented by Nico Popp on July 30th, 2021 | 10:12 CEST
CureVac, Desert Gold, Steinhoff: Here, gamblers get their money's worth
Where can speculative investors still find returns today? Are they bankruptcy candidates? Companies deeply entangled in legal disputes? Or fallen angels? Or are they small companies with a clear vision and experience in growth projects? We do the check and present three stocks.
Read
Commented by Carsten Mainitz on July 26th, 2021 | 13:55 CEST
BioNTech, Cardiol Therapeutics, CureVac - What is next?
Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?
Read
Commented by André Will-Laudien on July 23rd, 2021 | 11:37 CEST
CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?
Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...
Read
Commented by Nico Popp on July 20th, 2021 | 13:42 CEST
Siemens Healthineers, Cardiol Therapeutics, CureVac: Where there is music to be heard by the end of the year
Health is the highest good. Anyone who has ever experienced people having the "plug pulled" on them overnight can undoubtedly relate to this truism. Fortunately, medicine in this country is able to provide a quick remedy. A wide range of options are available for both diagnosis and therapy. In addition to laboratory analyses, imaging procedures also ensure that disease patterns can be narrowed down and, thus, treatments can be carried out in a targeted manner. Although our drugs are already powerful, new, more innovative approaches are emerging all the time. This development is also benefiting investors.
Read
Commented by Armin Schulz on July 14th, 2021 | 10:54 CEST
Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?
One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.
Read